United Therapeutics Corp. (UTHR) Director Sells $657,100.00 in Stock
United Therapeutics Corp. (NASDAQ:UTHR) Director Christopher Patusky sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $131.42, for a total value of $657,100.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $657,100. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Christopher Patusky also recently made the following trade(s):
- On Thursday, September 1st, Christopher Patusky sold 5,000 shares of United Therapeutics Corp. stock. The stock was sold at an average price of $122.73, for a total value of $613,650.00.
United Therapeutics Corp. (NASDAQ:UTHR) opened at 133.01 on Thursday. United Therapeutics Corp. has a 52-week low of $97.52 and a 52-week high of $164.04. The company has a market cap of $5.64 billion, a PE ratio of 9.00 and a beta of 1.39. The firm’s 50-day moving average price is $119.85 and its 200 day moving average price is $117.15.
United Therapeutics Corp. (NASDAQ:UTHR) last released its quarterly earnings data on Thursday, October 27th. The biotechnology company reported $4.36 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.38 by $0.98. The firm earned $408.20 million during the quarter, compared to the consensus estimate of $400.58 million. United Therapeutics Corp. had a return on equity of 41.78% and a net margin of 44.40%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.55 earnings per share. On average, equities analysts predict that United Therapeutics Corp. will post $16.29 EPS for the current fiscal year.
UTHR has been the subject of a number of recent research reports. Cowen and Company set a $144.00 price target on United Therapeutics Corp. and gave the stock a “buy” rating in a research report on Thursday, October 27th. Wedbush reaffirmed an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corp. in a research report on Thursday, July 28th. HC Wainwright reissued a “hold” rating on shares of United Therapeutics Corp. in a report on Friday, July 29th. Zacks Investment Research raised United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $137.00 price objective for the company in a report on Wednesday, September 28th. Finally, Argus reissued a “hold” rating on shares of United Therapeutics Corp. in a report on Tuesday, August 23rd. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $137.17.
Several large investors have recently added to or reduced their stakes in UTHR. Daiwa Securities Group Inc. increased its stake in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 150 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 190 shares during the last quarter. BancorpSouth Inc bought a new position in shares of United Therapeutics Corp. during the third quarter valued at about $224,000. Zweig DiMenna Associates LLC bought a new position in shares of United Therapeutics Corp. during the third quarter valued at about $224,000. Finally, Neuberger Berman Group LLC bought a new position in shares of United Therapeutics Corp. during the third quarter valued at about $233,000.
United Therapeutics Corp. Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.